MI meningiomas had the best outcomes and were enriched for meningiomas with non-NF2 driver mutations such as TRAF7, AKT1, and KLF4. Merlin expression was found to have pro-apoptotic tumor-suppressor effects in vitro and in vivo leading to increased response to cytotoxic therapies such as RT. Here, TRAF7 is linked to meningioma.